Clinical trials: Cannabidiol
Stage IV Ovarian Cancer, Testis Cancer, Refractory
CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors
This study is an open, exploratory clinical study to evaluate the safety and preliminary efficacy of Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells in patients with Claudin6, GPC3, Mesothelin, or AXL-positive advanced…
- Conditions
- Stage IV Ovarian Cancer, Testis Cancer, Refractory, Endometrial Cancer Recurrent, CAR NK
- Trial name
- NCT05410717
- Testing
- Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Odontalgia, Toothache
CBD for Dental Pain
The purpose of this study is to evaulate CBD as a therapeutic approach for dental pain. Eligible subjects presented with emergency dental pain will be give a single dose of Epidiolex (FDA-approved CBD) or placebo and will be…
- Trial name
- NCT04642404
- Testing
- Epidiolex 100 mg/mL Oral Solution
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Osteoarthitis
CBD Knee Osteoarthritis Study
Osteoarthritis of the knee is a common cause of pain in the US. The currently available medicines for knee osteoarthritis sometimes are not effective at relieving the pain or have unacceptable side effects.
- Trial name
- NCT07638189
- Testing
- Cannabidiol (CBD)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Tennessee
Epilepsy, Lennox Gastaut Syndrome
Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults
The primary objective of this study was to evaluate the efficacy of GWP42003-P as adjunctive treatment in reducing the number of drop seizures when compared with placebo in participants with Lennox-Gastaut syndrome (LGS).
- Trial name
- GWPCARE3 (NCT02224560)
- Testing
- GWP42003-P
- Where
- 29 sites in United States, France and 2 more
- Volunteers
- 225 people
- Sponsor
- Jazz Pharmaceuticals
Cannabis Use
Effect of Cannabidiol (CBD) on Vision and Driving
The use of cannabis with ∆9-tetrahydrocannabinol (THC) content has been shown to have negative effects on vision and driving. The use of other cannabinoids, such as cannabidiol (CBD), which is not attributed with a psychoactive…
- Trial name
- NCT06322303
- Testing
- CBD 15%, CBD 30%
- Where
- Spain
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Universidad de Granada
Advanced Breast Cancer, Anxiety
RCT of CBD for Anxiety in Advanced Breast Cancer
This research study is investigating use of a single dose of cannabidiol (CBD) to help manage anticipatory anxiety in participants with advanced breast cancer poised to undergo computed tomography (CT) or positron emission…
- Conditions
- Advanced Breast Cancer, Anxiety, CBD
- Trial name
- NCT04482244
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Dana-Farber Cancer Institute
Epilepsy, Dravet Syndrome
A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1)
To evaluate the safety and pharmacokinetics (PK) of multiple doses of GWP42003-P compared with placebo in children with Dravet syndrome.
- Trial name
- NCT02091206
- Testing
- GWP42003-P 5 mg/kg/day Dose, GWP42003-P 10 mg/kg/day Dose, GWP42003-P 20 mg/kg/day Dose
- Where
- 11 sites in United States, United Kingdom
- Volunteers
- 34 people
- Sponsor
- Jazz Pharmaceuticals
Seizure in Participants With Tuberous Sclerosis Complex, Seizure in Participants With Dravet Syndrome
Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures
This study will be conducted to evaluate the safety, pharmacokinetics (PK), and efficacy of adjunctive GWP42003-P in participants < 2 years of age with tuberous sclerosis complex (TSC), Lennox-Gastaut syndrome (LGS), or Dravet…
- Conditions
- Seizure in Participants With Tuberous Sclerosis Complex, Seizure in Participants With Dravet Syndrome, Seizure in Participants With Lennox-Gastaut Syndrome
- Trial name
- NCT04485104
- Testing
- GWP42003-P
- Where
- 11 sites in United States, Italy and 1 more
- Volunteers
- 3 people
- Sponsor
- Jazz Pharmaceuticals
Opioid Use Disorder
Reducing Pain and Opioid Use With CBD
This is a double-blind, placebo-controlled, parallel group study designed to assess the tolerability and efficacy of fsCBD and bsCBD, compared to a placebo control, to reduce opioid use, anxiety, and pain and improve sleep and…
- Trial name
- NCT05299944
- Testing
- Cannabidiol
- Where
- 2 sites in United States
- Volunteers
- 126 people
- Sponsor
- University of Colorado, Denver
Cannabis Intoxication
Effects of Cannabidiol (CBD) on a Fixed Dose of Delta-9-tetrahydrocannabinol (THC)
This study will evaluate the subjective and behavioral effects of cannabis products containing delta-9-tetrahydrocannabinol and cannabidiol
- Trial name
- NCT07870187
- Testing
- 0mg THC + 0mg CBD Brownie, 10mg THC + 0mg CBD Brownie, 10mg THC + 10mg CBD Brownie
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Cannabis Use Disorder
A Study of Cannabidiol in Young Adult Cannabis Users
The investigators will study the harm-reducing effect of hemp-derived CBD in non-treatment-seeking emerging adults who use cannabis regularly.
- Trial name
- NCT06569394
- Testing
- Broad Spectrum Cannabidiol (bsCBD) 400 mg
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of Colorado, Denver
Psoriatic Arthritis, Hand Osteoarthritis
CBD Treatment in Hand Osteoarthritis and Psoriatic Arthritis.
A randomized, placebo-controlled trial with blinded outcome assessments will be conducted to evaluate the efficacy and safety of CBD in patients with Hand-OA and PsA during a 12-week treatment period.
- Trial name
- NordCAN (NCT03693833)
- Testing
- Cannabidiol
- Where
- Denmark
- Volunteers
- 136 people
- Sponsor
- Aalborg University Hospital
Parkinson Disease
A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson's Disease
The major purpose of this study is to assess the efficacy of CBD on motor symptoms of Parkinson's Disease (PD), and secondarily to study the safety and tolerability of CBD and other efficacy, particularly regarding tremor in PD.
- Trial name
- NCT03582137
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- University of Colorado, Denver
Healthy
CBD, Immune Function, and Neural Health
Chronic inflammation, which is defined as a persistent, low-grade inflammatory response within the body, is associated with many of the negative health conditions which are prevalent in our society today.
- Trial name
- NCT04881539
- Testing
- Cannabidiol (CBD)
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Northern Colorado
Epilepsy, Lennox-Gastaut Syndrome
A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults
To evaluate the efficacy of GWP42003-P as adjunctive treatment in reducing the number of drop seizures when compared with placebo, in participants with Lennox-Gastaut Syndrome (LGS).
- Trial name
- GWPCARE4 (NCT02224690)
- Testing
- GWP42003-P 20 mg/kg/day Dose
- Where
- 24 sites in United States, Netherlands and 1 more
- Volunteers
- 171 people
- Sponsor
- Jazz Pharmaceuticals
Healthy
The Effects of Cannabidiol and ∆-9-THC in Humans
Cannabis is the most commonly used illicit substance in the US and herbal cannabis consists of a number of cannabinoids including Δ-9 THC and CBD.
- Trial name
- NCT01180374
- Testing
- Cannabidiol, Delta-9-THC
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Yale University
Drug Drug Interaction
KF2025#1 Trial: Ketamine, Cannabidiol and Cobicistat Interaction Study
Ketamine is a dissociative anesthetic developed approximately 60 years ago. Both ketamine and its isomer, esketamine, have been used for over 20 years in the treatment of treatment-resistant depression.
- Trial name
- KF2025#1 (NCT07462559)
- Testing
- Ketamine 10 mg/ml oral solution, UK special, Cobisistat Tybost 150 mg, Cannabidiol Epidyolex 100 mg/ml
- Where
- Finland
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
Absorption; Chemicals
Pharmacokinetic Study of a Novel Lipid Formulation of Cannabidiol Compared to a Standard Formulation
Cannabidiol (CBD) has been approved as a treatment for rare childhood epilepsies and could be an effective treatment for psychotic disorders, anxiety disorders and addictions.
- Trial name
- CLIP (NCT05032807)
- Testing
- Standard formulation, Novel formulation
- Where
- United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- King's College London
COVID-19, Cardiovascular Diseases
Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors
Non-critical patients, hospitalized within the previous 24 hours who tested positive for COVID-19 and have a prior history of cardiovascular disease (CVD) and/or significant risk factors for CVD will be treated for 28 days.
- Conditions
- COVID-19, Cardiovascular Diseases, Cardiovascular Risk Factor
- Trial name
- NCT04615949
- Testing
- Cannabidiol, pharmaceutically produced with < 5 ppm THC
- Where
- 20 sites in United States, Brazil and 1 more
- Volunteers
- 90 people
- Sponsor
- Cardiol Therapeutics Inc.
Dravet Syndrome (DS), Lennox-Gastaut Syndrome (LGS)
A Study to Investigate the Transition of Children From 'Artisanal" Cannabidiol (CBD) to Epidiolex
The goal of this clinical trial is to learn the best way to switch children with Lennox-Gastaut Syndrome (LGS) or Dravet Syndrome (DS) taking 'artisanal' (non pharmaceutical-grade) cannabidiol (CBD) to Epidiolex for treatment of…
- Trial name
- CANN-SWITCH (NCT06924827)
- Testing
- Epidiolex 100 mg/mL Oral Solution
- Where
- Canada
- Volunteers
- 25 people
- Sponsor
- Elizabeth Donner